Cargando…

BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia

Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanqing, Bi, Hailiang, Wang, Ying, Chen, Long, Pan, Jiaqi, Xu, Ping, Wang, Wei, Yang, Shaobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742103/
https://www.ncbi.nlm.nih.gov/pubmed/36518237
http://dx.doi.org/10.1097/BS9.0000000000000129
_version_ 1784848461573652480
author Zhang, Yanqing
Bi, Hailiang
Wang, Ying
Chen, Long
Pan, Jiaqi
Xu, Ping
Wang, Wei
Yang, Shaobin
author_facet Zhang, Yanqing
Bi, Hailiang
Wang, Ying
Chen, Long
Pan, Jiaqi
Xu, Ping
Wang, Wei
Yang, Shaobin
author_sort Zhang, Yanqing
collection PubMed
description Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR–ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored JAK2 V617F and BCR-ABL and observed multiple gene mutations, including IDH2, IDH1, ASXL1, KRAS, and RUNX1. It is important to be aware of this potentially clone evolution in disease progression.
format Online
Article
Text
id pubmed-9742103
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97421032022-12-13 BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia Zhang, Yanqing Bi, Hailiang Wang, Ying Chen, Long Pan, Jiaqi Xu, Ping Wang, Wei Yang, Shaobin Blood Sci Case Report Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR–ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored JAK2 V617F and BCR-ABL and observed multiple gene mutations, including IDH2, IDH1, ASXL1, KRAS, and RUNX1. It is important to be aware of this potentially clone evolution in disease progression. Lippincott Williams & Wilkins 2022-08-01 /pmc/articles/PMC9742103/ /pubmed/36518237 http://dx.doi.org/10.1097/BS9.0000000000000129 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS). https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Zhang, Yanqing
Bi, Hailiang
Wang, Ying
Chen, Long
Pan, Jiaqi
Xu, Ping
Wang, Wei
Yang, Shaobin
BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
title BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
title_full BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
title_fullStr BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
title_full_unstemmed BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
title_short BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
title_sort bcr-abl1 is a secondary event after jak2v617f in a patient with essential thrombocythemia who develop chronic myeloid leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742103/
https://www.ncbi.nlm.nih.gov/pubmed/36518237
http://dx.doi.org/10.1097/BS9.0000000000000129
work_keys_str_mv AT zhangyanqing bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia
AT bihailiang bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia
AT wangying bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia
AT chenlong bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia
AT panjiaqi bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia
AT xuping bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia
AT wangwei bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia
AT yangshaobin bcrabl1isasecondaryeventafterjak2v617finapatientwithessentialthrombocythemiawhodevelopchronicmyeloidleukemia